Gilead Sciences, Inc. (GILD) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$134.06
Price Target
$161.88
Target Range
$133.00 — $180.00
Analyst Rating
Buy
Forward P/E15.7x
Trailing P/E19.8x
Forward PEG—
Implied Growth+25.8%
Median Target$162.50
Analyst Spread29.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$133
-0.8%
Consensus
$162
+20.8%
Bull Case
$180
+34.3%
Valuation Model TargetsConfidence: 46/100
Bear$14
Base$134
Bull$137
GILD Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Gilead Sciences, Inc. (GILD) has a Wall Street consensus price target of $161.88, based on estimates from 58 covering analysts. With the stock currently trading at $134.06, this represents a potential upside of +20.8%. The company has a market capitalization of $166.40B.
Analyst price targets range from a low of $133.00 to a high of $180.00, representing a 29% spread in expectations. The median target of $162.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 37 analysts rating the stock as a Buy or Strong Buy,20 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GILD trades at a trailing P/E of 19.8x and forward P/E of 15.7x. Analysts expect EPS to grow +25.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $134.06, with bear and bull scenarios of $13.79 and $136.78 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+14.8%
Avg Forward P/E15.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 BMYBristol-Myers Squibb Company | $114.8B | $56.25 | $62.00 | +10.2% | Hold | 8.9x | 41 |
 AMGNAmgen Inc. | $177.6B | $329.06 | $350.76 | +6.6% | Buy | 14.7x | 38 |
 BIIBBiogen Inc. | $28.3B | $191.38 | $211.42 | +10.5% | Buy | 13.0x | 48 |
 REGNRegeneron Pharmaceuticals, Inc. | $73.7B | $709.10 | $865.68 | +22.1% | Buy | 15.3x | 48 |
 VRTXVertex Pharmaceuticals Incorporated | $108.1B | $425.00 | $552.27 | +29.9% | Buy | 22.2x | 56 |
 MRKMerck & Co., Inc. | $277.3B | $112.29 | $129.31 | +15.2% | Buy | 21.9x | 37 |
 PFEPfizer Inc. | $150.6B | $26.48 | $27.27 | +3.0% | Hold | 8.9x | 39 |
 JNJJohnson & Johnson | $536.2B | $222.51 | $249.27 | +12.0% | Buy | 19.2x | 40 |
 INCYIncyte Corporation | $19.5B | $97.77 | $109.50 | +12.0% | Buy | 13.1x | 44 |
Upside Potential Comparison
VRTXABBVREGNMRKJNJINCYBIIBBMYFull GILD Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy GILD Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See GILD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GILD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GILD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGILD — Frequently Asked Questions
Quick answers to the most common questions about buying GILD stock.
What is the GILD stock price target for 2026?
The consensus Wall Street price target for GILD is $161.88, representing 20.8% upside from the current price of $134.06. With 58 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GILD a buy, sell, or hold?
GILD has a consensus rating of "Buy" based on 58 Wall Street analysts. The rating breakdown is predominantly bullish, with 37 Buy/Strong Buy ratings. The consensus 12-month price target of $161.88 implies 20.8% upside from current levels.
Is GILD stock overvalued or undervalued?
With a forward P/E of 15.6878x, GILD trades at a relatively low valuation. The consensus target of $161.88 implies 20.8% appreciation, suggesting meaningful undervaluation.
How high can GILD stock go?
The most bullish Wall Street analyst has a price target of $180 for GILD, while the most conservative target is $133. The consensus of $161.88 represents the median expectation. Our quantitative valuation model projects a bull case target of $137 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover GILD stock?
GILD is heavily covered by Wall Street, with 58 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 37 have Buy ratings, 20 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GILD stock forecast?
The 12-month GILD stock forecast based on 58 Wall Street analysts shows a consensus price target of $161.88, with estimates ranging from $133 (bear case) to $180 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $134, with bear/bull scenarios of $14/$137.
What is GILD's fair value based on fundamentals?
Our quantitative valuation model calculates GILD's fair value at $134 (base case), with a bear case of $14 and bull case of $137. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
What is GILD's forward P/E ratio?
GILD trades at a forward P/E ratio of 15.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy GILD stock?
Wall Street analysts are very optimistic on GILD, with a "Buy" consensus rating and $161.88 price target (20.8% upside). 37 of 58 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GILD price targets vary so much?
GILD analyst price targets range from $133 to $180, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $161.88 consensus represents the middle ground. Our model's $14-$137 range provides an independent fundamental perspective.